Brainomix and Boehringer Ingelheim enter strategic partnership
Betsy Goodfellow | July 19, 2024 | News story | Research and Development | Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the care of patients with fibrosing lung disease in the US.
The project is expected to focus on the opportunity for AI imaging analysis utilising Brainomix’s 360 e-Lung on routine CT scans, with the intention of accelerating diagnosis timelines as well as improving access to treatment for people with fibrosing lung disease.
The partnership is intended to lead to the deployment of Brainomix’s FDA-approved e-Lung software to pulmonary centres and their referring sites. The data generated is hoped to validate the software’s value and emphasise the potential of digital technology in care for patients with fibrosing lung disease.
Dr Michalis Papadakis, chief executive officer and co-founder of Brainomix, commented: “There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and, it can take many years for a patient to be diagnosed. This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families.”
Betsy Goodfellow
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
PM Society and CIM launch new leadership programme for pharma marketers
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to …
